Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

TGFβ signalling has key roles in cancer progression: most carcinoma cells have inactivated
their epithelial antiproliferative response and benefit from increased TGFβ expression and …

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or
overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal …

Fecal microbiota transplantation (FMT) is highly effective against recurrent Clostridioides
difficile infection and is considered a promising treatment for other microbiome-related …

Background Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor
prognosis and no established therapy. Recently, encouraging responses to immune …

The gut microbiome has been shown to influence the response of tumors to anti–PD-1
(programmed cell death–1) immunotherapy in preclinical mouse models and observational …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research
into the mechanisms underlying response to ICB has predominantly focused on T cells; …

Developing strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …